Time To Antipsychotic Discontinuation After Remission Among Patients With Major Depressive Disorder With Psychotic Features At Tikur Anbessa Specialized Hospital: A Cross-Sectional Study.
No Thumbnail Available
Date
2026
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Addis Ababa Uinverstiy
Abstract
Background: Major depressive disorder with psychotic features is a severe and
disabling condition that requires both antidepressant and antipsychotic treatment. Most
international guidelines recommend maintaining antipsychotics for 4-6 months after
clinical remission, but data on actual duration and discontinuation practices in our
setting is limited for major depressive disorder with psychotic feature treatment.
Objective: The objective of this study is to determine the time to antipsychotic
discontinuation after remission among patients with major depressive disorder with
psychotic features at Tikur Anbessa Specialized Hospital, 2025.
Methods: A retrospective cross-sectional study was conducted among cases with
major depressive disorder at TASH who had a follow-up for the past 5 years. Census
method was used to select eligible patient records from the psychiatry follow-up EMR
registry. Data on demographics, clinical profiles, antipsychotic treatment duration,
remission, and discontinuation status was collected. Descriptive statistics was used to
summarize the data and chi-square test to measure the association between categorical
variables and results were presented using tables, graphs and charts.
Result: A total of 234 MDD patients were included in the study with a mean (±SD) age
of 39.6 ± 14.6 years, of whom 60 (25.6%) had MDD with psychotic features, and 62 (60
MDD-PF + 2 MDD as augmentation) patients initiated antipsychotic treatment, with
risperidone, 58.3% and olanzapine, 25% being the most commonly prescribed. Clinical
remission was achieved in 56.4% patients receiving antipsychotics. Prolonged
antipsychotic treatment was found in 65.7% patient, and 48.6% patients still continued
antipsychotic treatment following remission for a mean duration of 16.2 months (median:
15.5 months, IQR:9.4 months). Comorbid medical illness was the only factor
significantly associated with remission (p = 0.011).
Conclusion: The findings provide evidence on rational antipsychotics use and
treatment practices for patients with major depressive disorder with psychotic features
who start treatment at tertiary care setting. It supports the need to develop an
institutionalized or national treatment protocol; help to improve psychiatric care while
Vreducing the unnecessary prolonged antipsychotics use to ease the burden on both
patients and the healthcare system
Description
Keywords
Major depressive disorder, Psychotic features, Time to antipsychotic discontinuation, clinical remission, Ethiopia.